In this episode, Dr. Parsons and Dr. Battista discuss current and emerging medical therapies for the treatment of spinal muscular atrophy (SMA). They review safety, efficacy, and monitoring parameters of current agents, as well as adjuct therapies in the medication pipeline. This high-level overview includes:Review of FDA-approved medical therapies: nusinersen, onasemnogene abeparvovec-xioi, and risdiplamDiscussion of the safety, efficacy, and monitoring parameters for FDA approved medications, as well as adjuctive agents for medication therapy complicationsReview of ongoing clinical trials on anti-myostatin medications and discussion of the role these agents would play if approved by the FDAPresenters:Julie Parsons, MDCo-Director, Neuromuscular ClinicHaberfeld Family Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyChildren’s Hospital ColoradoDenver, ColoradoVanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, FPCNSenior Director of Nursing, Palliative CarePsychosocial Oncology and Palliative CareDana-Farber Cancer InstituteBoston, MassachusettsSupported by an educational grant from BiogenLink to full program:bit.ly/41kw2dKLink to CME: Claim credit -bit.ly/40fkDKD  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ver todos los episodios